Drugs & Targets FDA issues guidance on implementing decentralized elements in clinical trials September 20, 2024Vol.50 No.35
Drugs & Targets FDA issues guidance on integrating randomized controlled trials into routine clinical practice September 20, 2024Vol.50 No.35
Drugs & Targets Blenrep combinations in r/r multiple myeloma accepted for regulatory review in Japan September 20, 2024Vol.50 No.35
Drugs & Targets FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy September 13, 2024Vol.50 No.34
Drugs & Targets FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas September 13, 2024Vol.50 No.34
Drugs & Targets FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee September 13, 2024Vol.50 No.34
Drugs & Targets Astera Cancer Care, Knowtex collaborate to develop AI automation in oncology September 13, 2024Vol.50 No.34
Drugs & Targets FDA approves neoadjuvant/adjuvant Imfinzi for resectable NSCLC September 06, 2024Vol.50 No.33
Drugs & Targets FDA accepts Bristol Myers Squibb’s sBLA for Opdivo + Yervoy in unresectable HCC September 06, 2024Vol.50 No.33
